During the pandemic, Castor actually saw increased access to clinical trials—including medical device trials—made possible through the development and implementation of decentralized methods and/or remote technology, such as eConsent and telehealth. At Castor, we anticipate that 70% of clinical protocols will incorporate some element of decentralization in the future. Experts project that moving forward, at least one in five appointments with a healthcare provider will be conducted via telemedicine.

Our team firmly believes that DCT is great for both patients and the industry: applied correctly, incorporation of decentralized methods increases recruitment and retention offers a personalized participant experience, and
reduces the administrative burden on sites and study staff.

In this whitepaper, we will look at how EDC, eConsent, ePRO, and APIs enable researchers to easily conduct decentralized and hybrid clinical trials.

Download nowDownload now

Share article